MedTrace Logo

Exercise Study in Subjects With NAFLD

NCT03995056 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2022-08-11

No results posted yet for this study

Summary

Non-Alcoholic Fatty Liver Disease is the most common cause of chronic liver diseases. The benign non-alcoholic fatty liver, characterized by excessive fat accumulation, can evolve into non-alcoholic steatohepatitis and liver cancer.

The recommendation nowadays is a lifestyle change with physical exercise and diet to reduce liver fat and improve inflammation. Besides this, a leaky gut and dysbiosis have an impact on the liver, and exercise ameliorates the diversity of gut microbiota and permeability of the intestine.

The aim of this study is to find out a link between exercise and the gut-liver axis regarding the stage of liver adiposity and define exercise-responsive gut microbiome in NAFLD patients

Conditions

  • Non-Alcoholic Fatty Liver Disease
  • Gastrointestinal Microbiome
  • Exercise

Interventions

BEHAVIORAL

high-intensity aerobic interval training

The intervention group will follow a high-intensity interval training protocol on a cycle ergometer for 2 times per week and 1 time an individualised home workout program to have a total exercise amount of 3 hours. Leisure time physical activity at baseline as well as during the intervention period will be assessed by Polar Active devices.

Sponsors & Collaborators

  • European Commission

    collaborator OTHER

  • Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institute

    collaborator OTHER

  • Afekta

    collaborator UNKNOWN

  • Novogene

    collaborator UNKNOWN

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER

  • Clinical Microbiomics

    collaborator UNKNOWN

  • Kuopio Research Institute of Exercise Medicine

    collaborator OTHER

  • Kuopio University Hospital

    collaborator OTHER

  • University of Eastern Finland

    lead OTHER

Principal Investigators

  • Ursula Schwab, Prof · University of Eastern Finland

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-19
Primary Completion
2020-06-18
Completion
2020-06-18

Countries

  • Finland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03995056 on ClinicalTrials.gov